{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Using RECIST criteria, Objective Response evaluated every 2 months.","groups":[{"description":"2.5 mg by mouth (PO) daily","id":"OG000","title":"Letrozole"}],"paramType":"NUMBER","populationDescription":"Analysis was per protocol, only 9 of 12 eligible patients were evaluable for response.","reportingStatus":"POSTED","timeFrame":"2 month intervals for first 2 years","title":"Objective Response Rate Following Treatment With Letrozole","type":"PRIMARY","unitOfMeasure":"participants"}